Genetic variation in PRL and PRLR, and relationships with serum prolactin levels and breast cancer risk: results from a population-based case-control study in Poland

Table 4 Single-nucleotide polymorphisms associated with serum prolactin levels in the Polish Breast Cancer Study^a

Single-nucleotide polymorphism	Number	Geometric mean^b	95% CI	Ptrend
Premenopausal controls
PRLR
rs62355518
AA	140	11.16	8.81-14.15	0.01
AG	55	8.90	6.87-11.51
GG	5	10.61	6.60-17.05
rs10941235
GG	101	11.05	8.66-14.08	0.01
AG	90	9.24	7.21-11.85
AA	12	9.37	6.57-13.37
rs1610218
GG	192	10.47	8.26-13.28	0.01
AG	13	6.95	4.81-10.03
AA	0
rs34024951
GG	170	10.25	8.07-13.02	0.02
AG	34	8.38	6.27-11.19
AA	1	6.60	2.53-17.21
rs9292575
CC	162	10.07	7.97-12.71	0.03
AC	39	13.38	10.10-17.72
AA	3	7.32	4.19-12.80
Postmenopausal controls
PRL
rs849872
AA	300	7.63	6.23-9.35	0.01
AG	126	8.34	6.76-10.28
GG	13	9.69	7.10-13.24

^aA complete list of single-nucleotide polymorphism associations with serum prolactin concentrations can be found in Supplementary tables S3a and S3b in Additional file 1. ^bAdjusted for age, study site, time of blood collection, and time since last period (premenopausal only). CI, confidence interval; PRL, prolactin (gene); PRLR, prolactin receptor (gene).

ISSN: 1465-542X